Otology & Neurotology · 2001 · 310 citations · 15 references
MedicineOtolaryngologyPharmacotherapyClinical PharmacologyHearing AssessmentOtologyCochlear DisordersHearing ImpairmentHearing LossHyaluronic Acid TherapyIntratympanic TherapyObjective AudiometrySensorineural Hearing Loss EffectsSteroid Responsiveness
Prior animal studies and clinical observations at an ambulatory tertiary otologic referral center set the context for evaluating intratympanic dexamethasone in sudden sensorineural hearing loss. To evaluate the clinical value of intratympanic dexamethasone for sudden sensorineural hearing loss and to investigate optimal dosing and frequency. The study retrospectively reviewed 10 SSNHL patients receiving 0.5 mg intratympanic dexamethasone for 20 min and conducted an animal experiment randomizing 79 ears into control, IT‑DEX, IV‑DEX, and adjunctive agent groups, with post‑procedure audiometry and perilymph steroid measurements. IT‑DEX produced significant hearing improvement and higher perilymph steroid concentrations compared with IV‑DEX, supporting its use as an appropriate treatment for SSNHL.
To discuss the value of intratympanic dexamethasone (IT-DEX) perfusion for sudden sensorineural hearing loss (SSNHL), clinically and in an animal model.Retrospective case review of 10 patients with SSNHL treated with IT-DEX. The findings are correlated with this institution's previous findings from a study of IT-DEX in guinea pigs.Ambulatory tertiary otologic referral center.Sequential patients with SSNHL who chose IT-DEX treatment.Dexamethasone 0.5 mg was injected transtympanically and bathed the round window for 20 minutes. Animal study: 79 ears were randomized into five groups: control, IT-DEX versus intravenous (IV)-DEX, IT-DEX with histamine, IT-DEX with hyaluronic acid, and IT-DEX with dimethylsulfoxide.Clinical study: postprocedure audiometry. Animal study: perilymph steroid concentration.IT-DEX results in significant hearing improvement and in significantly higher perilymph concentration of steroid than IV-DEX.IT-DEX is an appropriate treatment option for the treatment of SSNHL. Further study of dosages and frequency of administration is warranted.
15
Autoimmune Sensorineural Hearing Loss
Brian F. McCabe · Annals of Otology Rhinology & Laryngology · 1979 · 931 citations
Medicine, Audiology, Otolaryngology +14